Not Applicable Submitted Trial Is A Bioequivalence Study clinical trials

Explore recruiting not applicable submitted trial is a bioequivalence study clinical trials.

Also recruiting in Europe

Not Applicable Submitted Trial Is A Bioequivalence Study trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase I double blinded, single-center, randomized, crossover study comparing the PK, PD, safety and tolerability of a single IV dose (1µg/kg) of LB-0702 and Nplate® in healthy volunteers.

Spain

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

Open-label, randomized, two-treatment, two-period, two-sequence, cross-over, single dose, bioequivalence study comparing ISOPRINOSINE® FORTE 100 mg/mL Syrup to ISOPRINOSINE® 500 mg tablets in healthy male and female subjects under fasting conditions.

Czechia

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

The bioavailability study of Dapagliflozin

Czechia

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

A Phase I, randomized, consecutive dose, double blind, parallel study comparing the PK, PD, immunogenicity, safety and tolerability of LB-0702 and Nplate® in healthy volunteers.

Spain, Portugal

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

An open label, randomized, three-period, three-sequence, crossover bioavailability study to assess the pharmacokinetic and safety profile of Valacyclovir Oral Suspension compared to Valtrex® extemporaneous suspension in normal, healthy subjects under fasting conditions and to investigate the effect of food on the bioavailability of Valacyclovir Oral Suspension.

Czechia

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

Single dose, open-label, laboratory blinded, randomised, 2-treatment, 2-period, 2-sequence, crossover bioequivalence study of test product Perampanel 12 mg film-coated tablets versus reference product Fycompa 12 mg film-coated tablets (Eisai GmbH) in healthy adult male and female subjects under fasting conditions.

Czechia

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

Not Applicable Submitted Trial Is A Bioequivalence Study trials by city

Not Applicable Submitted Trial Is A Bioequivalence Study in Toronto Not Applicable Submitted Trial Is A Bioequivalence Study in Vancouver Not Applicable Submitted Trial Is A Bioequivalence Study in Montreal Not Applicable Submitted Trial Is A Bioequivalence Study in Calgary Not Applicable Submitted Trial Is A Bioequivalence Study in Edmonton Not Applicable Submitted Trial Is A Bioequivalence Study in Ottawa Not Applicable Submitted Trial Is A Bioequivalence Study in Winnipeg Not Applicable Submitted Trial Is A Bioequivalence Study in Quebec City Not Applicable Submitted Trial Is A Bioequivalence Study in Hamilton Not Applicable Submitted Trial Is A Bioequivalence Study in Kitchener Not Applicable Submitted Trial Is A Bioequivalence Study in London Not Applicable Submitted Trial Is A Bioequivalence Study in Halifax Not Applicable Submitted Trial Is A Bioequivalence Study in New York Not Applicable Submitted Trial Is A Bioequivalence Study in Los Angeles Not Applicable Submitted Trial Is A Bioequivalence Study in Chicago Not Applicable Submitted Trial Is A Bioequivalence Study in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease